Jump to content

Ecopia Begins Patient Dosing in Cancer Trial

Recommended Posts

http://feed.insnews.org/v-cgi/feeds.cgi ... id=1746805

Apr 07, 12:22 PM

Quebec firm Ecopia BioSciences has began dosing its first patient in a phase I clinical trial of its anticancer product candidate ECO-4601.

The phase I study is designed to test the safety and tolerability of ECO-4601. Up to 30 patients suffering from one of six types of cancer, and who are refractory to current chemotherapies, will be recruited for this trial. Such cancers include glioblastomas, breast, prostate, ovarian, lung and colon cancers.

The clinical trial involves a 21-day cycle during which escalating dosages of the compound will be tested in different patients via continuous infusion using ambulatory pumps for 14 days, followed by a seven-day rest.

The investigation is taking place at the clinical research unit of the Sir Mortimer B. Davis - Jewish General Hospital (JGH), a McGill University Teaching Hospital.

ECO-4601 is a novel small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary brain tumor growth and other types of cancers. Just like well-known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from microorganisms that live in common soil.

However, unlike these drugs that were discovered many decades ago, ECO-4601 represents a new chemical class, which, according to Ecopia, is the fruit of a very unique drug discovery platform called the Decipher technology.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.